To investigate whether metformin is capable to regulate the activity of TGF-β signaling through targeting INHBA, we treated CRC cells with metformin and found the phosphorylation level of Smad2 was decreased in all cells receiving metformin treatment (Fig. 6f). Here, SMAD2 is linked to colorectal carcinoma.